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Rapidly Progressing, Diffuse Violaceous Nodules as a Presenting Symptom for 
Aggressive Acute Myeloid Leukemia
Case Presentation:
History of Present Illness: The patient was initially seen at our acute care 
clinic in May 2010 for evaluation of diffuse lumps that started three or four weeks 
prior. Patient noticed the lumps, which began on his chest and arms, after cutting 
maple trees in his backyard. Over several weeks, he noticed rapid progression and 
development of numerous nodules all over his body, but denied symptoms including 
pain, pruritus, bleeding, or changes in color. Patient reported mild shortness of 
breath, which he attributed to physical activites during that time. Review of systems 
for fever, chills, night sweats, weight loss, hemoptysis, nausea, vomiting, diarrhea, 
constipation, melena, or hematuria was unremarkable.
Medical History/Surgical History: Peptic ulcer disease, eczema, 
allergies, urinary blockage repair 
Family History: Lung cancer, prostate cancer
Medications: None 
Physical Examination: There are numerous pink to violaceous subcutaneous 
nodules measuring about 1-2cm on neck, arms, chest, abdomen, back, legs, and 
groin (figure 1). There was no palpable cervical, supraclavicular, axillary, or inguinal 
adenopathy. There was no hepatosplenomegaly. 
Laboratory Data: CBC with diff (05/14/10) is WNL except elevated neutrophils 
of 72% (40-70%). CMP is WNL (05/14/10). Lactate dehydrogenase (06/15/10) is 
1.5mmol/L (0.5-2.1mmol/L).
Studies: CT chest (5/26/10): “large right-sided pleural effusion with mediastinal 
shift…large anterior mediastinal mass with significant adenopathy concerning for 
lymphoma.”
Biopsy: 
CBLPath (D10NY1-0175157) 1. Left medial clavicle, 2. Left shoulder: “Dermal 
infiltration by a monomorphous population of medium-sized atypical cells with blast 
features partially effacing the normal architecture…positive staining of the atypical 
cells for CD56, CD43, CD23, CD117, and bcl-2, in majority of them positive staining 
for myeloperoxidase.” (Figure 2)
Health Network Laboratories (SM10-2582)  Bone marrow aspirate smear, clot 
section and core biopsy, right posterior iliac crest: “normocellular marrow with 
trilineage hematopoiesis involved by an acute myeloid leukemia.” 
Cytogenics by FISH revealed: negative NPMI and FLT3-ITD mutation, trisomies 
5 and 7 consistent with an AML, and partial deletions of the long arms of 
chromosomes 5,7, and 20.
Diagnosis: Aleukemic leukemia cutis
Disease Course: Twelve days after the initial presentation, patient developed 
rapid progression of shortness breath and was admitted to the hospital with a 
malignant pleural effusion. At that time, cytology of pleural effusion and bone 
marrow biopsy were done and revealed the diagnosis of acute myeloid leukemia. 
Patient rapidly deteriorated with multi-organ metastasis and died of fungal 
pneumonia thirty-seven days after the initial presentation. 
Therapeutic exercises - pelvic floor contraction and relaxation 
with emphasis on relaxation for downregulation, muscle stretching, 
and core stabilization
Manual Therapy:
•  Muscle energy techniques for pelvic obliquity
•  Trigger point release with ischemic compression
•  Scar tissue massage along cesarean scars
•  Modified Thiele massage for increased circulation, proprioception 
and relaxation
• ANA: negative
  –  Modified Thiele massage for increased circulation, 
proprioception and relaxation
Electrotherapy - Pathway MR-20 sEMG and Synergy software 
program utilized for assessment and visual feedback training for 
pelvic floor relaxation and coordination
Self-Care Education - patient education regarding 
pathophysiology, body mechanics, posture training, relaxation 
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Discussion:
Leukemia cutis (LC) is defined as cutaneous infiltration by malignant leukocytes of 
myeloid or lymphoid lineage, resulting in clinical skin lesions. LC has been reported 
in patients with acute myeloid leukemia (AML), chronic myeloproliferative disease, 
including chronic myelogenous leukemia (CML), myelodysplastic syndrome, and 
myelodysplatic/lymphoproliferative diseases. Overall, LC occurs in 10-15% of patients 
with AML. In the majority of cases, LC presents concomitantly or after a diagnosis 
of systemic leukemia has been made. Rarely, in less than 10% of cases, LC has 
been reported to occur in the absence of systemic symptoms before bone marrow 
or peripheral blood involvement. The term “aleukemic leukemia cutis” or “primary 
extramedullary leukemia” has been used to describe this rare phenomenon, which has 
been shown to occur predominately in patients with AML. 
Clinically, LC can cause non-specific reactive skin lesions or present with single or 
multiple lesions of violaceous, red-brown, or hemorrhagic papules, nodules, and 
plaques. LC lesions present most commonly on the head, neck, and trunk. It also 
favors sites of previous or existing inflammation. Aleukemic LC lesions are usually 
papulonodular and diffusely distributed. Histopathologically, findings of LC vary with the 
type of leukemia, but typically show diffuse infiltrate or tumor nodules of leukemic cells 
in the dermis. Frequently, there are dense peri-vascular and peri-eccrine infiltrates and 
lining of single cells through the interstitial collagen in the superficial and deep dermis. 
More importantly, immunophenotype assessment is essential in diagnosing the specific 
type of leukemia (figure 3). Furthermore, specific chromosomal abnormalities have 
been shown to be associated with certain types of LC. For example, abnormalities of 
chromosome 8 have been detected more frequently in LC patients with AML. 
Development or presence of LC does not provide relevant epidemiologic, and or, clinical 
data regarding sex, age, WBC count, hemoglobin concentration, platelet count, and 
fibrinogen level. However, higher serum levels of lactate dehydrogenase and or β2-
microglobulin, which correlate to the negative prognostic factors, have been associated 
in patients with LC than in patients without LC. In general, the development of leukemia 
cutis suggests a poor prognosis. Recent study suggested that chronic myelomonocytic 
leukemia in the presence of LC have significantly increased risk of transformation 
to AML and intensive extramedullary involvement with shortened survival. It has 
been reported that about 88% of patients with leukemia cutis die within one year of 
the diagnosis. In contrast to adult leukemic patients, LC does not portend a worse 
prognosis in patients with congenital leukemia. 
Figure 1:  
Diffusely distributed numerous pink to violaceous subcutaneous nodules.  
Figure 2: 
(A-D) H&E histopathologic findings: A(2X), B(4X), C(10X)- Diffuse dense infiltrate involving the dermis and subcutis with sparing of the 
upper papillary dermis; D(40X)- At high-power magnification, large hyperchromatic cells and mitotic figures are seen.
(E-S) Immunohistochemical findings.
Figure 3:  
Diagnostic Immunophenotypic Profile of Leukemia Cutis
ALL-acute lymphoblastic leukemia; AML-acute myeloid leukemia; AMoL-acute monocytic leukemia; AMMoL-acute myelomonocytic 
leukemia; ATLL- adult-Tcell leukemia/lymphoma; CLL-chronic lymphocytic leukemia; CML-chronic myeloid leukemia; MPO-myeloperoxidase; 
SS-Sezary syndrome; TdT-terminal deoxynucleotidyl transferase; T-PLL-T-cell prolymphocytic leukemia (adopted from: Cho-Vega JH, 
Medeiros LJ, Prieto VG, Vega F. Leukemia Cutis. Anatomic Pathology 2008;129:130-142.)
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